Skip to content

Comstock Inc. LODE Bioleum — Profit Loss

Other segment segments

Corporate And Other
-$3.52M+23.4%

Similar metrics at other companies

UFP Industries, Inc. logo
UFPIAll Other Segments — Profit Loss
$3.55M+42.0%
Gevo logo
GEVOGevo — Profit Loss
-$17.19M+11.9%
Walker & Dunlop logo
WDCorporate — Profit Loss
-$33.51M-78.9%
Guardian Pharmacy Services logo
GRDNCorporate — Profit Loss
$13.54M+46.1%
PTC Therapeutics logo
PTCTLife Science — Net Income Loss
-$2.81M-100%
AnaptysBio, Inc. logo
ANABBiopharma Company — Net Income Loss
-$50.48M-7.0%

Other financials

Income statement

See full
Revenue$313.5K-60.1%
Gross profit-$286.4K-184%
Operating income-$8.9M-27.1%
Net income-$9.4M-3.2%
EPS (diluted)-$3.01-450%

Balance sheet

See full
Cash & equivalents$53.0M+212%
Total debt$257.3K-98.8%
Total equity$156.4M
Total assets$218.1M+28.6%

Cash flow

See full
Operating cash flow-$5.8M-17.3%
CapEx--100%
Free cash flow-$3.5M+2.7%

Valuation

See full
Market cap$302.13M+177%
Enterprise value$249.42M+118%
P/S279.4×+247×

Profitability

See full
Gross margin-116.4%-177pp
Operating margin-3,703.7%-7,510pp
Net margin-4,010%-13,152pp
FCF margin-462.3%-171pp

Returns & leverage

See full
Return on equity-51.5%-12.9pp
Debt / equity
Current ratio4.5×+2.1×

Where this comes from

Reported directly by Comstock Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Comstock Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Comstock Inc.'s bioleum — profit loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Comstock Inc.'s bioleum — profit loss?
Comstock Inc. (LODE) reported bioleum — profit loss of -$5.67M in Q1 2026.
How has Comstock Inc.'s bioleum — profit loss changed year-over-year?
Comstock Inc.'s bioleum — profit loss decreased by 107.0% year-over-year, from -$2.74M to -$5.67M.
What does bioleum — profit loss mean?
Represents the final net financial result for the Bioleum segment after accounting for all operating and non-operating revenues and expenses. This is the ultimate measure of the segment's contribution to the company's overall financial performance.